January 9, 2026
Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.
Today’s edition tracks Congress choosing stability on medical cannabis while leaving rescheduling to the administration, a clean hedge with real downstream stakes. We also cover hemp THC forcing the channel question into the open, and Massachusetts posting record sales as the work shifts from headlines to governance.
This briefing is supported by our day job at THC Group and by The Hybrid podcast with former regulators Shawn Collins and Erik Gundersen.
🏛️ Appropriations hedging
🛒 Mainstream shelf pressure
💵 Governance season
Enjoy your weekend.
Start here — the day’s most important development, decoded for impact.
📌 What Happened: The House passed a three-bill appropriations package funding Commerce Justice Science, Energy and Water, and Interior and Environment through September 30th. The bill preserves the rider that blocks DOJ from using funds to interfere with state and territorial medical marijuana programs. Negotiators also removed language that would have barred DOJ and DEA from using FY 2026 funds to reschedule marijuana. The Senate is now the hinge, with a Monday January 12th cloture vote on the motion to proceed on the calendar and a January 30th funding deadline motivating the pace. The deal moves medical cannabis back into Congress’s comfort zone and leaves scheduling in the hands (or lap) of the White House.
💡 Why It Matters: This is Congress choosing the status quo with minimal exposure and real upside. If rescheduling stalls, gets enjoined, or turns messy, lawmakers can point to agency process and keep their fingerprints off the outcome. If rescheduling lands clean, Republicans still get the downstream win of calmer markets, expanded research posture, and tax timing that starts to matter once a final rule takes effect. Think not just mid-terms, but the 2028 presidential cycle. The medical rider keeps getting easier to renew because the list of protected programs grows and members represent those patients, those providers, and those state officials. Appropriations has become the closest thing to durable federal cannabis policy because it rewards repetition and punishes risk. Washington is protecting itself while keeping the lights on. Reform theory is not driving this vote.
🧠 THC Group Take: This is pure Washington political risk management. Congress protected medical again because compassion, constituency, and self-interest line up neatly there. Congress also declined to choke off rescheduling through spending language because the Trump administration is willing to carry the responsibility and the litigation that follows. That division of labor is deliberate, and it leaves everyone watching two calendars at once: the agency calendar for a final rule and effective date, and the court calendar for the first injunction attempt. It also creates an opening for critics to treat every messy state market headline as an argument against federal movement.
The industry loves big narratives. Appropriations loves small verbs. The rider still rewards the businesses that can prove they can follow rules like adults, with controls that hold up when someone comes looking for shortcuts. Rescheduling can still shift tax and capital posture, yet it only becomes real on an effective date, and the first serious opponent will aim straight at that date. Congress is letting the administration go first, and it will take credit for stability while keeping distance from the risk.
Fast-moving headlines, flagged for what matters.
President Trump’s Schedule III directive could reopen a path for Washington, D.C. because the congressional rider blocking adult-use sales is tied to Schedule I. If DOJ completes rescheduling, the District gains room to build a regulated sales market with taxes and licensing under local law. Congressional analysis also warns that broader tetrahydrocannabinols phrasing in appropriations has been used as a second leash. That leaves D.C. in planning mode while Congress decides how tight it wants the next rider to be. The practical move is Council groundwork now, with opening day controlled by appropriations text and federal scheduling timing. (Marijuana Moment)
A federal government funding deal includes hemp language that would effectively wipe out most intoxicating hemp products when it takes effect in November 2026. Michigan is moving in parallel after the Senate advanced legislation to bring intoxicating hemp under the Cannabis Regulatory Agency with testing and tighter controls. Licensed operators are framing this as a public health and enforcement gap built around products sold without consistent age checks and without regulated lab standards. Hemp advocates are pushing for a regulated lane and a longer runway that preserves disciplined, age-gated low-dose models while shutting down synthetics and kid-forward packaging. The market consequence in Michigan looks modest on the licensed side, because many hemp buyers still do not shop in dispensaries. (Detroit Free Press)
Wisconsin lawmakers are debating multiple bills to rein in intoxicating hemp products as the federal definition tightens and a late 2026 ban looms. One approach builds a regulated lane with testing, certification, labeling, and a clear 21-plus age floor designed to separate compliant hemp products from illegal marijuana under state law. A competing Republican proposal would impose an alcohol-style three-tier structure, and critics warn it could squeeze smaller sellers that rely on direct-to-consumer economics. Another proposal would mirror the federal ban and effectively wipe out most products, which runs into the governor’s veto math. The consequence is near-term uncertainty for retailers and farmers, with pressure rising to write rules that reward compliant, age-gated models and eliminate the worst shelf behavior. (Wisconsin Public Radio)
South Carolina lawmakers are debating whether to regulate hemp-derived THC products or ban them, with senators signaling they want a decision this session. The state has allowed intoxicating hemp sales to spread across convenience retail with no statewide age floor, and that posture is collapsing politically. A House-passed proposal would set 21 as the minimum age for hemp beverages and edibles, and senators are weighing taxes, dosage limits, and tighter channel rules. Industry voices are pressing for standards that keep compliant sellers alive while pushing bad actors off the shelf. The consequence is a fast-approaching compliance line for retailers, with federal timing making delay harder to defend. (WIS-TV)
Sprouts Farmers Market is launching hemp-derived THC beverages across 120 stores in Texas and Florida starting next week. The lineup spans seven brands, with stated dosages running from 2mg to 10mg THC and some products paired with CBD or CBG. A grocery rollout from a national chain forces the channel question into the open, including age-gating, labeling, and whether mainstream retail can meet enforcement expectations. It also accelerates the definitional fight, because major retailers need bright lines and defensible compliance routines. The consequence is simple: regulators will be asked to choose between banning the shelf or regulating it like an adult category. (BevNET)
Massachusetts adult-use cannabis sales hit $1.65 billion in 2025 with 46.3 million transactions on the year. Price compression and the usual growing pains are real, and plenty of operators are feeling that squeeze every week in payroll, pricing, and procurement. Not to mention people that don’t pay their bills. The numbers still refuse to cooperate with the “mess” narrative, and credit is due to the team that built a functional statewide program and kept it running while the market matured in public. The Commonwealth reported $265 million in adult-use cannabis tax revenue for fiscal 2025, which has moved this category into baseline budgeting and away from novelty politics. The 2026 consequence is productive tightening: renewals that mean something, smarter oversight of saturation and capital stress, and social consumption that works in real doors. Some critics are trying to create a mess so they can be seen cleaning it up. The program needs disciplined governance, and the data is a better guide than anyone’s personal storyline. (WWLP)
Massachusetts social consumption rules took effect January 2nd, and the headlines are still ahead of the doors. The Commission took years to get from the first round of social consumption talk to final regulations, which tells you how much friction lives in the details before a single spot opens. Municipal opt-in will determine where and how many, and most towns will take their time deciding whether they want consumption in the first place. The Cannabis Control Commission still has to turn regulation into applications, guidance, and inspection posture that local officials can administer without improvising. The first winners will be municipalities that want the tourism upside and can move approvals without getting spooked by predictable pushback. The consequence is a rollout that looks slow to the public and feels familiar to anyone who has watched local control stretch timelines in Massachusetts. (High Times)
Massachusetts election officials scheduled a January 13th hearing after opponents filed a complaint accusing an anti-legalization campaign of deceptive signature gathering. The complaint alleges circulators described the petition as unrelated issues and presented only the back page for signature. A pre-hearing conference is set for January 12th, keeping the timeline tight. The campaign disputes the claims, and Secretary William Galvin has questioned whether challengers can invalidate enough signatures in time. If the measure survives and reaches voters, it sets up a 2026 shock fight that preserves possession and gifting while repealing legal sales and home grow. (Marijuana Moment)
State Sen. Adam Ebbin will resign February 18th to join Gov. Abigail Spanberger’s administration as a senior adviser at the Virginia Cannabis Control Authority. His exit triggers a rapid special election in Northern Virginia and reshuffles committee leadership mid-session. Candidates are already moving, and party leaders now have to run an accelerated nomination process. Ebbin has been central to Virginia’s cannabis policy architecture, so the agenda-setting effect is real even if the direction stays the same. The consequence is timing risk, with drafting authority and political leverage shifting during a session that could decide whether Virginia finally builds a functioning adult-use retail framework. (ARLnow)
New Hampshire’s House voted 208 to 135 to advance a legalization bill that includes taxes, licensing, and home cultivation. The measure now goes to House Finance and must clear another House vote before it reaches the Senate. The Senate remains the choke point, and Gov. Kelly Ayotte has said she would veto legalization. That keeps the fight centered on vote counting and coalition discipline rather than rollout mechanics. The consequence is continued regional isolation until the Senate changes posture or the governor’s veto threat stops being dispositive. (Seacoastonline)
A Kentucky lawmaker filed legislation to send adult-use legalization to the ballot instead of forcing it through the General Assembly. The proposal would ask voters to legalize adult use for people 21 and older, with possession up to one ounce and up to five plants for personal use if approved. The sponsor is framing it as a legitimacy question after decades of enforcement harm. Republican leadership called it dead on arrival and reiterated a medical-first posture. The consequence is a public pressure test that makes legislators choose between a vote of the people and continued legislative gatekeeping while medical implementation is still underway. (WKYT)
Seven years after the Guam Cannabis Act, Guam still has no licensed, operational legal retail cannabis business, and a legislative roundtable pinned the failure on process more than ideology. The Department of Revenue and Taxation director reported 15 applicants since adult-use legalization, with only two active and none near completion. A leading applicant described a multi-agency clearance gauntlet where staff are unfamiliar with cannabis approvals and the business has renewed its annual establishment license three times while waiting. Industry witnesses described lost land deals and collapsed funding after delays blew past statutory timelines. The consequence is investor flight and a credibility problem that keeps patients and consumers reliant on the same unofficial market the law was meant to replace. (Post Guam)
Curaleaf plans to seek shareholder approval to domesticate as a Delaware corporation through a plan of arrangement. The company says the move aligns its corporate home with its U.S. operating footprint and does not change day-to-day operations. Shares and equity awards would convert on a one-for-one basis into equivalent Delaware classes. The vote requires a two-thirds shareholder approval plus court sign-off. The consequence is a cleaner U.S. corporate wrapper that can matter for governance, financing flexibility, and how future transactions get structured. (Cannabis Business Times)
William Blair reaffirmed its buy stance on Scotts Miracle-Gro as management points to rescheduling as a tailwind for its Hawthorne cannabis business. Scotts has framed reclassification as a catalyst that improves Hawthorne’s growth outlook and deal attractiveness. Management has also said it expects to combine Hawthorne with a cannabis company early in fiscal 2026 as it sharpens focus on core lawn and garden. This is a packaging story as much as a market story, with cannabis exposure being made easier to finance and easier to value. The consequence is a more deliberate set of deal options landing right as federal posture becomes less hostile to institutional capital. (Insider Monkey)
ASTM’s D37 cannabis committee elected David Vaillencourt as chair and Darwin Millard as vice chair for the 2026 to 2027 term. D37 standards keep migrating from voluntary guidance into de facto expectations when regulators and labs need something defensible to point to. David and Darwin have the credibility to keep the work practical and usable across jurisdictions. Watch the committee’s output on testing, quality systems, and terminology, since those decisions often show up later in audit posture and lab disputes. The consequence is a slowly rising compliance floor that rewards mature operators and pressures everyone else to catch up. (Cannabis Business Times)
American Air Filter International launched a free program inviting cultivators to submit used grow-room filters for analysis. The goal is operational intelligence: what facilities are catching, how quickly performance degrades, and where mold risk concentrates. The program also frames filtration as worker safety infrastructure, which is where regulators and insurers tend to converge. The testing looks at efficiency and pressure drop, paired with microscopy to examine particulate buildup. The consequence is more cultivation scrutiny on HVAC maintenance schedules and documented controls, since those details decide whether a facility runs clean or turns into a recurring remediation story. (Cannabis Industry Journal)
The 2025 to 2030 Dietary Guidelines for Americans removed the old one drink for women and two drinks for men benchmark. It replaces that standard with general guidance to drink less for better health. Beverage alcohol trade groups praised the moderation framing, while public health advocates criticized the loss of a clear reference point. Those federal words still matter, because states, employers, and insurers borrow them for prevention messaging and risk screening tools. The consequence is a renewed fight over labeling, retail rules, and taxes, with both sides using the same guideline language to justify very different policy outcomes. (BeverageDaily)
Garden Path Fermentation filed suit in federal court challenging a federal rule that blocks cider, mead, and fruit wine producers from listing vintage years on labels. The complaint targets the Alcohol and Tobacco Tax and Trade Bureau and argues the rule suppresses truthful commercial speech while grape wine can use the same information. The case seeks declaratory and injunctive relief, setting up a clean fight over equal treatment across categories. If the plaintiff wins, regulators will face pressure to justify other category carveouts that have hardened into habit. The consequence is more scrutiny of beverage labeling lines that feel arbitrary and increasingly hard to defend. (Washington Beer Blog)
From the hearing room to the comment section — we’re watching it all.
🏈 Calvin Johnson, Detroit Lions legend, is talking openly about using cannabis during his playing career to manage pain. The admission puts more daylight on how the NFL’s pain culture pushes players toward self-directed remedies while league policy and federal law keep drifting on separate tracks. (Detroit Free Press)
🍸 High Times CEO Josh Kesselman is calling the recent wave of “scromiting” stories alcohol industry propaganda, arguing Big Alcohol is trying to blunt momentum for cannabis beverages. The useful read here is less the insult and more the playbook: as hemp drinks hit mainstream shelves, public health narratives become a competitive arena, and sloppy claims travel faster than data. (TMZ)
🧪 California is funding cannabis research with a regulator’s agenda in mind: synthetics, cardiac risk, flavors, and why consumers keep buying outside licensed channels. The results will not stay academic, because they will be used to justify rule changes and enforcement priorities. (UCLA Health)